Papers/PMID:34004189
Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.
The Journal of pediatrics2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
all-trans-retinol — decreases bronchopulmonary dysplasia of any grade at 36 weeks
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×1“Vitamin A therapy reduced BPD among survivors (RR=0.86 [95% CI: 0.75–0.98]) with a greater effect among infants at low risk than high risk of BPD or death (p=0.01 for interaction).”
Quoted verbatim from Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.. - Study
- RCT
- Duration
- 4 weeks
- Dose
- 5000 IU intramuscularly three times weekly for 4 weeks versus sham procedure
- Population
- Infants of 401-1000 g birth weight on respiratory support at 24 hours, randomised to intramuscular vitamin A or sham; BPD among survivors to 36 weeks postmenstrual age (post hoc reanalysis of the NICHD Neonatal Research Network trial)
Effect 0.86 risk ratio, 95% CI 0.75 to 0.98
Should Vitamin A Injections to Prevent Bronchopulmonary Dysplasia or Death Be Reserved for High-Risk Infants? Reanalysis of the National Institute of Child Health and Human Development Neonatal Research Network Randomized Trial.2021PMID:34004189Permalink